Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $9.9 million.

  • Mirum Pharmaceuticals' Other Non-Current Assets rose 8434.94% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 8434.94%. This contributed to the annual value of $5.4 million for FY2024, which is 2921.97% up from last year.
  • Mirum Pharmaceuticals' Other Non-Current Assets amounted to $9.9 million in Q3 2025, which was up 8434.94% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Other Non-Current Assets registered a high of $9.9 million during Q3 2025, and its lowest value of $1.2 million during Q2 2023.
  • For the 5-year period, Mirum Pharmaceuticals' Other Non-Current Assets averaged around $3.3 million, with its median value being $1.8 million (2021).
  • In the last 5 years, Mirum Pharmaceuticals' Other Non-Current Assets soared by 79125.0% in 2021 and then crashed by 3423.51% in 2023.
  • Mirum Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $1.8 million in 2021, then dropped by 22.62% to $1.4 million in 2022, then skyrocketed by 201.37% to $4.2 million in 2023, then increased by 29.22% to $5.4 million in 2024, then surged by 84.28% to $9.9 million in 2025.
  • Its last three reported values are $9.9 million in Q3 2025, $6.8 million for Q2 2025, and $5.5 million during Q1 2025.